BioPorto A/S Stock price

Equities

BIOPOR

DK0011048619

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Copenhagen 11:59:34 2024-03-27 am EDT 5-day change 1st Jan Change
1.308 DKK -2.10% Intraday chart for BioPorto A/S -2.53% -37.42%
Sales 2023 * 31.1M 4.5M Sales 2024 * 40M 5.79M Capitalization 497M 71.87M
Net income 2023 * -56M -8.1M Net income 2024 * -38M -5.5M EV / Sales 2023 * 16 x
Net cash position 2023 * - 0 Net cash position 2024 * - 0 EV / Sales 2024 * 12.4 x
P/E ratio 2023 *
-8.18 x
P/E ratio 2024 *
-13.1 x
Employees 33
Yield 2023 *
-
Yield 2024 *
-
Free-Float 89.17%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on BioPorto A/S

1 day-2.10%
1 week-2.53%
Current month-17.22%
1 month-20.15%
3 months-36.20%
6 months-18.56%
Current year-37.42%
More quotes
1 week
1.30
Extreme 1.302
1.35
1 month
1.30
Extreme 1.3
1.60
Current year
1.30
Extreme 1.3
2.35
1 year
1.07
Extreme 1.07
3.85
3 years
1.00
Extreme 1.002
5.70
5 years
1.00
Extreme 1.002
8.24
10 years
1.00
Extreme 1.002
8.24
More quotes
Managers TitleAgeSince
Chief Executive Officer 64 13-07-17
Chief Tech/Sci/R&D Officer - 20-11-30
Chief Tech/Sci/R&D Officer - 22-06-30
Members of the board TitleAgeSince
Chairman 65 21-04-28
Director/Board Member 74 21-04-28
Chief Executive Officer 64 13-07-17
More insiders
Date Price Change Volume
24-03-27 1.308 -2.10% 203,767
24-03-26 1.336 +1.21% 430,815
24-03-25 1.32 -0.60% 230,646
24-03-22 1.328 +2.00% 223,710
24-03-21 1.302 -2.98% 864,009

Delayed Quote Nasdaq Copenhagen, March 27, 2024 at 11:59 am EDT

More quotes
Bioporto A/S is a Denmark-based company engaged in the development and marketing of in vitro diagnostic (IVD) assays. The Company's portfolio comprises five product categories: The Neutrophil gelatinase-associated lipocalin (NGAL) Test, which is a test for diagnosing acute kidney injury; NGAL Enzyme-linked immunosorbent assay (ELISA) kits, which supplies NGAL for the development of medicines for estimating side-effects that are harmful to kidneys; Mannan-binding Lectin (MBL) ELISA kit, which offers monoclonal MBL antibodies that are responsible for the activation of immune response; Antibodies, including monoclonal antibodies used in a range of research areas, such as microbiology, biomarkers, peptide hormones and plasma proteins; and Activated Protein C with Protein C Inhibitor Complex (APC-PCI), a biomarker applied to patients with sepsis and thrombotic and hemostatic disorders. In addition, the Company is a parent of BioPorto Diagnostics A/S.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
1.308 DKK
Average target price
5 DKK
Spread / Average Target
+282.26%
Consensus
  1. Stock
  2. Equities
  3. Stock BioPorto A/S - Nasdaq Copenhagen